Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 5, 2005, Pages 529-537

  Venkatakrishnan, Karthik ^b   Culm, Kerry E ^b   Ehrenberg, Bruce L ^b   Harmatz, Jerold S ^b   Corbett, Kathleen E ^b   Fleishaker, Joseph C ^b   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Adinazolam; Alprazolam; Digit Symbol Substitution Test; Electroencephalography; N desmethyl adinazolam; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ADINAZOLAM; ALPRAZOLAM; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; NORADINAZOLAM; SEDATIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; ELECTROENCEPHALOGRAM; HUMAN; HYSTERESIS; KINETICS; MALE; MOOD DISORDER; PARAMETER; PLASMA HALF LIFE; RANDOMIZED CONTROLLED TRIAL; SEDATION;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; CROSS-OVER STUDIES; ELECTROENCEPHALOGRAPHY; EMOTIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PSYCHOMOTOR PERFORMANCE;

EID: 17644395684     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269105     Document Type: Article

References (41)

1. Dunner D, Myers J, Khan A, Avery D, Ishiki D, Pyke R. Adinazolam - a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression. J Clin Psychopharmacol. 1987;7:170-172.
2. Amsterdam JD, Kaplan M, Potter L, Bloom L, Rickels K. Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. Psychopharmacology (Berl). 1986;88:484-488.
3. Davidson JR, Beitman B, Greist JH, et al. Adinazolam sustained-release treatment of panic disorder: a double-blind study. J Clin Psychopharmacol. 1994;14:255-263.
4. Wilcox CS, Ryan PJ, Morrissey JL, et al. A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:979-993.
5. Fleishaker JC, Friedman H, Pollock SR. Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers. Pharm Res. 1991;8:162-167.
6. Fleishaker JC, Phillips JP, Smith TC, Smith RB. Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects. Pharm Res. 1989;6:379-386.
7. Sethy VH, Collins RJ, Daniels EG. Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol. 1984;36:546-548.
8. Fleishaker JC, Friedman H, Pollock SR, Smith TC. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers. Clin Pharmacol Ther. 1990;48:652-664.
9. Fleishaker JC, Hulst LK, Smith TC, Friedman H. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers. Eur J Clin Pharmacol. 1992;42:287-294.
10. Fleishaker JC, Smith TC, Friedman HL, Hulst LK. Separation of the pharmacokinetic/pharmacodynamic properties of adinazolam mesylate and N-desmethyladinazolam mesylate following oral and IV administration of each compound in man. Drug Invest. 1992;4:155-165.
11. Fleishaker JC, Hulst LK, Ekernas SA, Grahnen A. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. J Clin Psychopharmacol. 1992;12:403-414.
12. Fleishaker JC, Sisson TA, Sramek JJ, Conrad J, Veroff AE, Cutler NR. Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery. J Clin Pharmacol. 1993;33:463-469.
13. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
14. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther. 1989;250:134-140.
15. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. 1996;276:370-379.
16. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324:1691-1698.
17. Greenblatt DJ, Javaid JI, Locniskar A, Harmatz JS, Shader RI. Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. J Chromatogr. 1990;534:202-207.
18. Locniskar A, Greenblatt DJ. High-performance liquid chromatographic assay of adinazolam and its desmethyl metabolite. J Chromatogr. 1988;424:215-217.
19. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther. 1989;45:356-365.
20. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther. 1994;56:100-111.
21. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther. 1992;52:139-150.
22. Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997;37:693-703.
23. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm. 1981;9:367-388.
24. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25:358-371.
25. Greenblatt DJ, Harmatz JS, von Moltke LL, Shader RI. Pharmacokinetics and pharmaoodynamics. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven; 1995:849-858.
26. Greenblatt DJ, Sethy VH. Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology (Berl). 1990;102:373-378.
27. Greenblatt DJ. Principles of pharmacokinetics and pharmacodynamics. In: Nemeroff CB, Schatzberg AF, eds. The American Psychiatric Press Textbook of Pyschopharmacology. Washington, DC: American Psychiatric Press; 1995:125-136.
28. Greenblatt DJ, von Moltke LL, Ehrenberg BL, et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med. 2000;28:2750-2757.
29. Stanski DR. Pharmacodynamic modeling of anesthetic EEG drug effects. Annu Rev Pharmacol Toxicol. 1992;32:423-447.
30. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16:143-166.
31. Campbell DB. The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology (Berl). 1990;100:433-450.
32. Schwinghammer TL, Kroboth PD. Basic concepts in pharmacodynamic modeling. J Clin Pharmacol. 1988;28:388-394.
33. Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology (Berl). 1989;99:34-39.
34. Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998;50:265-274.
35. Ajir K, Smith M, Lin KM, et al. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology (Berl). 1997;129:265-270.
36. Mandema JW, Danhof M: Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet. 1992;23:191-215.
37. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther. 1998;64:237-247.
38. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998;64:278-285.
39. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther. 1998;64:553-561.
40. Koopmans R, Dingemanse J, Danhof M, Horsten GP, van Boxtel CJ. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther. 1988;44:14-22.
41. Lau CE, Heatherington AC. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits. J Pharmacol Exp Ther. 1997;283:1119-1129.